These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18565962)

  • 21. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic obstructive pulmonary disease megatrials: taking the results into office practice.
    Stoloff SW
    Am J Med Sci; 2011 Aug; 342(2):160-7. PubMed ID: 21512392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics of COPD: a role for the β2-adrenergic receptor gene?
    Jensen CS; Dahl M
    Lancet Respir Med; 2014 Jan; 2(1):3-4. PubMed ID: 24461881
    [No Abstract]   [Full Text] [Related]  

  • 24. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
    Dalal AA; Candrilli SD; Davis KL
    Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tiotropium in combination with placebo, salmeterol, or fluticasone salmeterol for chronic obstructive pulmonary disease: possible confounding effect of treatment withdrawal?
    Brown SM
    Ann Intern Med; 2007 Dec; 147(12):882; author reply 882-3. PubMed ID: 18087061
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
    Rabe KF; Timmer W; Sagkriotis A; Viel K
    Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.
    Dransfield MT; Bailey WC
    Expert Opin Pharmacother; 2004 Aug; 5(8):1815-26. PubMed ID: 15264996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
    Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J
    Respiration; 2013; 86(4):280-7. PubMed ID: 23880883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
    Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB; Tillie-Leblond I; Attali V; Bavelele Z; Lagrange O
    Respir Med; 2011 Feb; 105(2):250-8. PubMed ID: 20702076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD.
    Maltais F; Mahler DA; Pepin V; Nadreau E; Crater GD; Morris AN; Emmett AH; Ferro TJ
    Eur Respir J; 2013 Aug; 42(2):539-41. PubMed ID: 23904549
    [No Abstract]   [Full Text] [Related]  

  • 33. [Dyspnea and quality of life in chronic obstructive pulmonary disease].
    Sanjuás C
    Arch Bronconeumol; 2002 Oct; 38(10):485-8. PubMed ID: 12372199
    [No Abstract]   [Full Text] [Related]  

  • 34. [New studies refute steroid opponents. COPD--after all a case for corticosteroids?].
    Calverley P
    MMW Fortschr Med; 2003 Jun; 145(24):20. PubMed ID: 12866294
    [No Abstract]   [Full Text] [Related]  

  • 35. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies.
    Miravitlles M; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2009; 4():185-201. PubMed ID: 19516917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New therapy for managing moderate to severe chronic obstructive pulmonary disease.
    Chou A; D'Urzo AD
    Can Fam Physician; 2014 Apr; 60(4):352-4. PubMed ID: 24733327
    [No Abstract]   [Full Text] [Related]  

  • 37. Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology.
    Seemungal T; Stockley R; Calverley P; Hagan G; Wedzicha JA
    COPD; 2007 Sep; 4(3):177-83. PubMed ID: 17729060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Rev Port Pneumol; 2005; 11(6):587-9. PubMed ID: 16514718
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reported pneumonia in patients with COPD: findings from the INSPIRE study.
    Calverley PMA; Stockley RA; Seemungal TAR; Hagan G; Willits LR; Riley JH; Wedzicha JA;
    Chest; 2011 Mar; 139(3):505-512. PubMed ID: 20576732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.